Bio clude Case Study BioXclude Allograft Placental Tissue Membrane in Combined Regenerative Therapy in the Treatment of a Periodontal Intrabony Defect: A Case Report Background: Combined regenerative
both the epithelial cells and connective
tissue into the space, to facilitate contain-
carefully moved into final position using
clot. This case report documents the use
regenerative therapy for the treatment of
Case Summary: An otherwise healthy 63
The amoxicillin was continued for 7 days
at a dose of 875 mg twice daily. Patient
tion and treatment on the maxillary left
second premolar (tooth # 13) (Figure 1).
separate clinical entity to the pulp (Figure
dine twice daily to manage postoperative
2). The patient was scheduled for surgery
to treat this tooth which had a questio-
Prior to surgery, the patient was rinsed
and then every other month for up to six
Upon reflection, the defect was debrided
due to a periapical lesion that developed
of all soft tissue, followed by scaling and
Results: At two and four weeks, the
cline and 5 milliliters of sterile water
demonstrated (Figure 7 and Figure 8). At
BB) applied to it. Freeze-dried allograft
suggested very good bone fill (Figure 10)
gently packed into and slightly overfilled
Bio clude Case Study Discussion: This case report provides
evidence that the use of BioXclude, in a
intrabony defect, provides for a success-
of laminin-5, a protein with a high affinity
critical to retain. If it were lost, an implant
for cellular adhesion of gingival epithelia
cells3,4. This provides a bioactive matrix
Adding this tooth into a fixed prosthesis
already existing bridge into one that had
8 units. Both of these two options would
have incurred considerable time and cost
for the patient. The alternative choice of
totally unacceptable to this patient.
walls. However, this same characteristic
and sterilized graft of human amnion and
chorion tissue. These two layers of tissue
requires it to be placed directly over a
there is limited gingival tissue available
to advance over the adapted membrane.
Placental allografts are new to the field of
in accordance with stringent regulations
tive approaches for osseous lesions. This
benefits for using BioXclude to achieve a
privileged and as such, does not elicit a
successful clinical regenerative outcome
foreign body inflammatory response1. Its
Paul S. Rosen, DMD, MS has a practice limited to periodontics, dental implants and regenerative therapies and is located in Yard- ley, PA. He is a Clinical Associate Professor of Periodontics at the Baltimore College of Dental Surgery at the University of Maryland Dental School in Baltimore, MD and a member of Snoasis Medical’s Clinical Advisory Board. He can be reached by phone at (215) 579-0907 or by email at [email protected] References:
1. Chen E, Tofe A. A literature review of the safety and biocompatibility of amnion tissue.
J Imp Clin Adv Dent. 2009; vol 2, No. 3: 67-75.
2. Park C, Kohanim S, Zhu L et al. Immunosuppressive property of dried human amniotic
membrane. Opthalmic Res 2009; 41: 112-113. www.snoasismedical.com
3. Baharvand H, Heidari M, Ebrahimi, et al. Proteomic analysis of epithelium-denuded
human amniotic membrane as a limbal stem cell niche. Mol Vis 2007; 18(13): 1711-1721.
BioXclude™ is a trademark of Snoasis Medical, Inc. 2009.
4. Pakkala T, Virtanen I, Oksanen J, et al. Function of laminins and laminin-binding
Manufactured by Surgical Biologics, a MiMedx Group Company.
integrins in gingival epithelial cell adhesion. J Perio 2002; 73(7): 709-719. Redefining Perioplastic Surgery
bebe stores, Inc. EPO 90/0 Plan Welcome to WellNet! The information below is a general description of your plan benefits and is not meant to be a complete list or complete description of available services. Please contact WellNet at 800-442-1101 with specific questions about your program. PRESCRIPTION DRUG COPAYS RETAIL (up to 30 day supply) MAIL SERVICE (up to 90 da
P R A X I S Z E N T R U M F R A U E N H E I L K U N D E REPRODUKTIONSMEDIZIN – PRÄNATALDIAGNOSTIK - OPERATIONEN Gemeinschaftspraxis Dr. Müller & Busecke PI 53 Patienteninformation Ferti PROTEKT – Sicherung der Fertilitätsreserve des Mannes Dieses Informationsblatt wendet sich an Männer und Jugendliche nach der Pubertät, deren Fruchtbarkeit durch bevorstehende Medikamentenein